Cambridge Healthtech Institute’s 10th Annual

Clinical and Translational Biomarkers

Precision Medicine, Liquid Biopsy, and Clinical Trials

June 2-4, 2020


The promise of precision medicine has been driven by the need to accurately predict patient response to therapy while ensuring drug efficacy and safety. Reducing costs and the time required for drug development is also a driving force in the use of biomarkers. Cambridge Healthtech Institute’s 10th annual Clinical and Translational Biomarkers meeting will cover novel biomarker discovery, clinical and analytical biomarker validation, and the role of biomarkers in clinical decision making.

BIOMARKERS FOR PATIENT SELECTION

Precision Medicine Initiatives at the National Cancer Institute
Tracy G. Lively, PhD, Chief, Diagnostics Evaluation Branch, Deputy Associate Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute

Accelerating Oncology Drug Development by Patient Stratification
Hua C. Gong, MD, PhD, Senior Director, Head of Genomics Biomarker Development, Navigate Biopharma, a Novartis Company

Patient Selection Biomarkers for Neurodegenerative Diseases
Michael Baratta, PhD, Scientific Director, Clinical Biomarker Development Innovation, Takeda

LIQUID BIOPSY IN PRECISION MEDICINE

Liquid Biopsies Enabling Precision Medicine
Jonathan Beer, Director, FPM Lead of Disruptive Technologies, Novartis Precision Medicine

Translational Biomarkers: From Discovery to the Clinic
Katherine Call, PhD, Senior Director, Head, Proteogenomics, Sanofi Translational Sciences

Personalized Serial Detection of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients with Pediatric Cancers
Rachel Nga Wan Tam, PhD, Senior Scientific Researcher, Oncology Biomarker Development, Genentech

Evaluation of NGS Assay Sensitivities in Liquid Biopsies for MRD
Amelia Raymond, Scientist, Translational Medicine, AstraZeneca

Liquid Biopsy for Brain Tumors
Brian V. Nahed, MD, MSc, Associate Professor, Neurosurgery, Harvard Medical School; Associate Director, Neurosurgery Residency Program, Massachusetts General Hospital

BIOMARKER ANALYSIS FOR MECHANISM OF RESPONSE AND RESISTANCE

Overview of Genomic Biomarkers in Clinical Trials
Chetan Deshpande, Clinical Biomarker Assay Lead, Pfizer

Predictive Molecular Marker for C. Difficile Infection Recurrence
Xuemei Zhao, PhD, Senior Principal Scientist, Merck

High Resolution, High Throughput Single Vesicle Analysis
John Nolan, PhD, Professor, The Scintillon Institute